Final Day for Early Investor Perks
Final Month to Invest in a Breakthrough Cure for Osteoarthritis

Osteoarthritis Affects 600M People. We’re Making the Cure. 

INVEST NOW
$2.30

share price

Cytonics has successfully surpassed its target minimum and is still accepting investments.

Valuation Cap:

$23,000,000

Min. Investment:

$490

Min. Investment:

$490

Security Type

SAFE

A SAFE stands for a Simple Agreement for Future Equity. We're offering a contract that converts to equity when triggered by an event like an acquisition or IPO. The contract guarantees your shares at a pre-specified maximum valuation or at the next investment valuation (whichever is more favorable to you), potentially making your investment even more valuable after a triggering event.

Valuation Cap:

$23,000,000

Min. Investment:

$490

Round Size:

$4,300,000

Security Type

SAFE

A SAFE stands for a Simple Agreement for Future Equity. We're offering a contract that converts to equity when triggered by an event like an acquisition or IPO. The contract guarantees your shares at a pre-specified maximum valuation or at the next investment valuation (whichever is more favorable to you), potentially making your investment even more valuable after a triggering event.
+

Problem

Over $240B3 Is Spent On Inferior Treatments*

Osteoarthritis (OA) is the most common joint disease characterized by the erosion of protective cartilage tissue within joints. Often thought of as a disease of the elderly, OA is also prevalent among athletes. To date, the joint pain and inflammation associated with OA is merely managed, and there are no effective therapies that target the root cause of the disease to reverse its progression and restore the damaged cartilage. Over $240B is spent on palliative treatments (pain killers, corticosteroids, and hyaluronic acid injections) that bring temporary symptomatic relief. This must change.

*Market size computed based on 6x prevalence of OA compared to rheumatoid arthritis and global sale of TNF-alpha inhibitors.

Learn More
01:15

What Is Osteoarthritis?

Osteoarthritis is a degenerative joint disease defined by the breakdown of the protective cartilage tissue that provides support within articular joints. This breakdown is caused by a cascade of molecular mechanisms that result in the hyper-activity of a class of enzymes called “proteases.” These proteases act like molecular “Pacmen,” chewing up the cartilage tissue, rendering the joint brittle, inflamed, immobile, and painful. OA can affect any joint, from the knees, ankles, toes, shoulders, elbows, wrists, fingers, and hips, to the vertebrae within the spine.

Existing treatments address the symptoms, not the root cause.

OA is projected to impact 25% of US adults by 2030.

About 600 million People suffer from OA Worldwide.

OA Robs People Of Their Mobility And Destroys Their Quality Of Life.

INVEST NOW

Solution

A Paradigm Shift In Osteoarthritis Treatment

Cytonics has developed breakthrough OA treatments based on a naturally occurring blood protein called “Alpha-2-macroglobulin” (A2M). A2M is a potent, broad-spectrum protease inhibitor that is able to inhibit the proteases involved in cartilage degradation in arthritic joints.

Testimonials From Physicians, Patients, And Investors

[Dr. Scuderi] took out some of my blood and he put it into the centrifuge and they did what they had to do and then he reinjected the A2M protein back into my knee. Before he did the procedure, I could not bend my knee, I could not walk upstairs. I really couldn't do anything. In fact, I was using a brace on my knee just to give me some support because the whole knee felt like it was going to cave in. A few days after the procedure I was walking and we were walking the dogs and the swelling seemed to have been going down.

- Gail Lynn

I came with Gail when she discovered Dr. Scuderi and what he can do for arthritis. I went for an x-ray. Very simply, he did the same procedure. He took blood from my arm and put it in a centrifuge and got the protein out and injected it in my shoulder. And I’ve been great. We had nothing but success with this protein shot.

- Robert Lynn

- Gail Lynn & Robert Lynn

I partially tore my ACL in a skiing accident in Switzerland. After an unnecessary arthroscopy revealed I was not a candidate for ACL reconstruction, my knee was swollen and stiff for 6 weeks. Then I had a single treatment of Cytonics A2M therapy, APIC. Within 2 days the swelling and stiffness was gone and hasn’t returned 6 months later. I was so impressed with these results that I have been evangelizing for APIC treatment to my doctors and friends ever since.

Even if I need another treatment soon, a couple APIC injections per year with no noticeable side effects and no drugs is closer to a miracle-treatment than I imagined possible before my experience with Cytonics’ product. Joint injuries can be physically and emotionally debilitating, but medical advancements like this make now the best time in history to tear one’s ACL.

- Gabe

“I was an early investor in Cytonics as the technology is timely in unraveling the etiology of Low back pain. The future will be assaying for specific biomarkers to determine not only the cause of pain but the potential for improvement with certain interventions. As a busy spine surgeon for the last 25 years the direction that Cytonics is proceeding in attempting to minimize clinical failures through their Autologous Platelet Integrated Concentration (APIC) System is breathtaking and timely.”

- Alexander R Vaccaro, MD, PhD, MBA

I have been using Cytonics’ alpha2- macroglobulin kits to treat various joint pains mostly in the knee. This is part of my regenerative medicine practice. I’ve seen remarkable results such that I have suggested that my wife and my son undergo treatments as well as patients. The treatments were remarkably successful in both of them. I am very pleased and I’m looking forward to having this product available more easily off-the-shelf and approved by insurance. I expect a huge demand for it. Thank you.

- Laurence  Rosenfield, MD

Cytonics’ recombinant drug development program is anchored in robust preclinical data indicating that the proteinase inhibitor alpha-2-macroglobulin critically inhibits cartilage breakdown in models of osteoarthritis. Cytonics has developed a lead recombinant drug candidate, a variant of human alpha-2-macroglobulin that possesses a unique and improved bioactivity profile. Cytonics’ strategic efforts are exciting as they target the development of a first biologic therapy for patients suffering from osteoarthritis.”

- Martin Angst, MD

“I suffered prolonged pain from a partial tear in my right Achilles tendon. I am very familiar with this pain as I ruptured and had my left Achilles surgically repaired. After almost eight months of therapy and various treatments, Richard Grossman, MD told me about Cytonics and the available A2M treatment. I received my first injection in April of 2018 and within weeks the large nodule in my Achilles had shrunk significantly. While I was feeling much better and able to start playing basketball and tennis again for the first time in ten months, I still felt a little pain. I went back for a 2nd injection in November of 2018 and the pain has been reduced to only minor pain with NO LIMITATIONS. The A2M therapy has given me my sports and mobility life back and I have recommended this treatment to all of my friends.”

- Daryle Bobb

“I was an early investor in Cytonics as the technology is timely in unraveling the etiology of Low back pain. The future will be assaying for specific biomarkers to determine not only the cause of pain but the potential for improvement with certain interventions. As a busy spine surgeon for the last 25 years the direction that Cytonics is proceeding in attempting to minimize clinical failures through their Autologous Platelet Integrated Concentration (APIC) System is breathtaking and timely.”

- Alexander R Vaccaro, MD, PhD, MBA

I have been using Cytonics’ alpha2- macroglobulin kits to treat various joint pains mostly in the knee. This is part of my regenerative medicine practice. I’ve seen remarkable results such that I have suggested that my wife and my son undergo treatments as well as patients. The treatments were remarkably successful in both of them. I am very pleased and I’m looking forward to having this product available more easily off-the-shelf and approved by insurance. I expect a huge demand for it. Thank you.

- Laurence  Rosenfield, MD

Cytonics’ recombinant drug development program is anchored in robust preclinical data indicating that the proteinase inhibitor alpha-2-macroglobulin critically inhibits cartilage breakdown in models of osteoarthritis. Cytonics has developed a lead recombinant drug candidate, a variant of human alpha-2-macroglobulin that possesses a unique and improved bioactivity profile. Cytonics’ strategic efforts are exciting as they target the development of a first biologic therapy for patients suffering from osteoarthritis.”

- Martin Angst, MD

[Dr. Scuderi] took out some of my blood and he put it into the centrifuge and they did what they had to do and then he reinjected the A2M protein back into my knee. Before he did the procedure, I could not bend my knee, I could not walk upstairs. I really couldn't do anything. In fact, I was using a brace on my knee just to give me some support because the whole knee felt like it was going to cave in. A few days after the procedure I was walking and we were walking the dogs and the swelling seemed to have been going down.

- Gail Lynn

I came with Gail when she discovered Dr. Scuderi and what he can do for arthritis. I went for an x-ray. Very simply, he did the same procedure. He took blood from my arm and put it in a centrifuge and got the protein out and injected it in my shoulder. And I’ve been great. We had nothing but success with this protein shot.

- Robert Lynn

- Gail Lynn & Robert Lynn

I partially tore my ACL in a skiing accident in Switzerland. After an unnecessary arthroscopy revealed I was not a candidate for ACL reconstruction, my knee was swollen and stiff for 6 weeks. Then I had a single treatment of Cytonics A2M therapy, APIC. Within 2 days the swelling and stiffness was gone and hasn’t returned 6 months later. I was so impressed with these results that I have been evangelizing for APIC treatment to my doctors and friends ever since.

Even if I need another treatment soon, a couple APIC injections per year with no noticeable side effects and no drugs is closer to a miracle-treatment than I imagined possible before my experience with Cytonics’ product. Joint injuries can be physically and emotionally debilitating, but medical advancements like this make now the best time in history to tear one’s ACL.

- Gabe

“I suffered prolonged pain from a partial tear in my right Achilles tendon. I am very familiar with this pain as I ruptured and had my left Achilles surgically repaired. After almost eight months of therapy and various treatments, Richard Grossman, MD told me about Cytonics and the available A2M treatment. I received my first injection in April of 2018 and within weeks the large nodule in my Achilles had shrunk significantly. While I was feeling much better and able to start playing basketball and tennis again for the first time in ten months, I still felt a little pain. I went back for a 2nd injection in November of 2018 and the pain has been reduced to only minor pain with NO LIMITATIONS. The A2M therapy has given me my sports and mobility life back and I have recommended this treatment to all of my friends.”

- Daryle Bobb

The Next Generation in OA Therapy: CYT-108

Cytonics is currently working on a second-generation novel biopharmaceutical drug product – a genetically engineered variant of the A2M protein that has been intelligently designed to enhance the potency and activity of the natural A2M molecule.

Cytonics has proven that CYT-108 is significantly more potent than the natural A2M protein in preclinical experiments and has demonstrated that CYT-108 is safe to administer and prevents damage to cartilage (and other joint tissues) associated with osteoarthritis.

Cytonics is preparing for a first-in-human Phase 1 clinical trial anticipated to start in early Q1 2023. The company is currently conducting their final preclinical study to submit to the FDA in an Investigational New Drug (IND) application in Q3 2021.

Pre-Clinical Research On CYT-108: The Data Is In, And CYT-108 Works

Preliminary preclinical data demonstrates CYT-108’s efficacy in preserving the cartilage and surrounding tissues (e.g., synovial membrane) in a large animal model of post-traumatic osteoarthritis. Regular treatments of CYT-108 (or placebo saline solution) were injected into the damaged joints along a 12-week treatment window. Pieces of the cartilage and surrounding tissues were examined to measure the cartilage-protective effects of CYT-108 and its ability to encourage joint remodeling/healing. In summary, the administration of CYT-108 into the joint restored the damage caused by osteoarthritis to the cartilage and synovial membranes by ~60%. Read more here.

Roadmap

Path To Clinical Trials: CYT-108

Use of Funds

Since our last raise (2021), we have accomplished all of our milestones in pursuit of advancing CYT-108 into FDA human clinical trials. These accomplishments include manufacturing GMP-grade CYT-108 protein for our final preclinical study (“IND-enabling toxicology study”) and an imminent Phase 1 clinical trial (planned for Q1 2023). Now, we are calling on investors to help fund our first-in-human Phase 1 clinical trial and advance CYT-108 one step closer to FDA approval.

A Revolutionary Treatment

Once approved by the FDA, CYT-108 will be the first and only OA therapy on the market that targets the root molecular cause of the disease. CYT-108 will not only alleviate the joint pain and inflammation associated with osteoarthritis, but it will reverse the cartilage damage and progression of OA, providing patients with a long-term and effective therapy solution.

INVEST NOW
Cytonics Is Pioneering Breakthrough Treatments For Osteoarthritis

Invest in our next growth phase as we prepare for Phase 1 human clinical trials.

Thank you! Please check your inbox for the Cytonics Investor Deck!
Oops! Something went wrong while submitting the form.

Pipeline

Development Pipeline

In addition to the FDA-approved APIC therapy and novel CYT-108 biopharmaceutical under development, we also have an OA biomarker test in the market and are pursuing FDA approval for a modified APIC device called the “APIC Mini” (a more cost-effective solution for smaller joints).

BIOPHARMACEUTICALS

IND (Drug) Pathway to FDA Approval

CYT-108

We are currently pursuing pre-clinical studies for our recombinant A2M, CYT-108. We have contracted a research organization, Goodwin Biotechnology, to purify GMP/GLP quantities of CYT-108 for pre-clinical experiments and FDA clinical trials.

MEDICAL DEVICES

510(K) Pathway to FDA Approval

APIC

Our APIC system for concentrating the naturally occurring A2M in the patient’s blood has been approved by the FDA and used to treat over 7,000 patients.

APIC Mini

We have developed a smaller, less expensive APIC system dubbed “APIC Mini” to provide physicians with a solution for treating small joints (such as fingers) that do not require as much volume. The APIC Mini also has the potential for veterinary applications.

DIAGNOSTICS

Clinical Laboratory Test
INVEST NOW

Milestones

Company Milestones

Find out what’s happened since our last raise here

Johnson & Johnson Development Corp. is a large shareholder.
 Over 8,000 patients successfully treated with the APIC therapy.
$22 million raised from institutions and individuals.
Awarded $1.8M in NIH grants to pursue OA treatments.
IP Portfolio includes 22 issued US and international patents with 5 patents pending.
CYT-108 has demonstrated positive preclinical safety and efficacy data.

An effective treatment for Osteoarthritis would have a tremendous impact on both human well-being and the economic burden of the disease, as over $240B is spent treating Osteoarthritis per year.

Cytonics discovered alpha-2-macroglobulin (A2M) as a potent inhibitor of the cartilage-destroying proteases. A2M is found naturally in the blood. While the natural levels of A2M are too low to lend any therapeutic benefit to damaged joints, Cytonics theorized that delivering high concentrations of A2M directly into the joint space could bind to and inhibit the proteases, slowing and eventually halting the progression of Osteoarthritis.

Our Autologous Platelet Integrated Concentration (APIC) system selectively enriches for A2M from a patient’s own blood, delivering high concentrations of the therapeutic A2M to the joint and eliminating all of the damaging molecules.

This is achieved by drawing and centrifuging the patient’s blood, then filtering out all of the proteins that could cause damage to the joint (such as proteases and inflammatory cytokines) and selectively concentrating A2M.

APIC’s successful treatment of over 7,000 patients nationwide led to the development of CYT-108, the synthetic A2M variant with test data showing a substantial improvement in cartilage protection. See the results here.

Roadmap

Good Manufacturing Practices (GMP)

is a standard developed by the FDA to ensure the quality of the drug and reproducibility of the manufacturing process. GMP certification requires rigorous testing of the process and final drug product, and GMP-certified material is needed to conduct human clinical trials.

An Investigational New Drug Application (IND)

is filed with the FDA prior to initiating Phase 1 human trials. The IND contains all preclinical data supporting the safety and efficacy of the drug in animals, details of the manufacturing process, and a description of the drug product itself. An IND must be filed and approved by the FDA (90 days) before conducting human clinical studies.

FDA pre-IND Submission for Osteoarthritis

Pre-IND application provides opportunity for dialogue with FDA prior to conducting Phase 1 clinical study for Osteoarthritis. This is critical to designing an effective, efficient human clinical trial

FDA pre-IND
Meeting for Osteoarthritis

FDA will provide feedback on preclinical data and guidance on GLP preclinical and Phase 1 human clinical trials for Osteoarthritis

FDA pre-IND Submission for COVID

Submission of COVID-19 preclinical study proposal and Phase 1 human trial protocol for review and feedback prior to conducting any studies

FDA pre-IND
Meeting for COVID

FDA will provide feedback on proposed preclinical and Phase 1 human trials for CYT-108 as a treatment for COVID. FDA will also discuss Emergency Use Authorization to expedite the drug approval process for COVID drugs

GLP Preclinical Study for Osteoarthritis

Repeat the large animal preclinical study under GLP conditions, as per the FDA’s recommendation in the pre-IND meeting (4) for Osteoarthritis held on September 25 (Q3 2020)

Preclinical COVID-19 Study

Preclinical study to assess the safety and efficacy of CYT-108 as a therapeutic for COVID-19. Levels of SARS-CoV-2  virus and inflammatory cytokines in the blood and lungs will be measured

Reg A Capital Raise Complete

Reg A+ issuance of preferred equity complete. Potential NASDAQ listing following close. Funds will be used to complete drug development, pursue Phase 1 human clinical trials for CYT-108 as a treatment for osteoarthritis, and preclinical studies to assess the safety and efficacy of CYT-108 as a treatment for COVID-19

IND Filing for Osteoarthritis Phase 1 Clinical Study

FDA will provide feedback on proposed preclinical and Phase 1 human trials for CYT-108 as a treatment for COVID. FDA will also discuss Emergency Use Authorization to expedite the drug approval process for COVID drugs

Phase 1 Trial Begins

Phase 1 human clinical study commences upon FDA acceptance of IND filing. Establishing safety is the primary goal. Efficacy will be scored by measuring a reduction in patient-reported pain

Team

Gaetano Scuderi, MD is the Founder of Cytonics Corporation. Dr. Scuderi is a fellowship-trained (UCSD, San Diego, CA) spine surgeon who has practiced medicine since 1993. He was also appointed to Clinical Assistant Professor in the Department of Orthopedic Surgery of Stanford University. He graduated medical school from State University of New York (Buffalo, NY) and completed his Residency at University of Miami School of Medicine (Miami, FL). Dr. Scuderi has published over 45 scientific articles and has lectured world-wide. Dr. Scuderi currently practices orthopedic surgery in Jupiter, FL.

In addition to his practice and his role with Cytonics, Dr. Scuderi is a 4th degree black-belt in Jiu Jitsu and the founder/principle instructor of Scuderi Self Defense (Jupiter, FL). Dr. Scuderi’s love for this martial art is only surpassed by his passion for helping the sick and elderly reclaim their mobility and quality of life.

Gaetano Scuderi, MD

Founder and Chairman of the Board

Mr. Bose has over 15 years’ experience in biotechnology research development and healthcare investment banking. He began his career as a systems biology researcher at the University of Virginia and Johns Hopkins University, advancing the field of proteomics and elucidating the molecular drivers of various cancers. Mr. Bose then worked for two boutique healthcare investment banks in the South Florida region, bringing his expertise to the healthcare deal diligencing team. As CEO & President of Cytonics, Mr. Bose coordinates capital raising efforts, manages the company’s preclinical and clinical trials for lead drug candidate “CYT-108”, oversees the Freedom to Operate patent prosecution strategy, and develops relationships with potential strategic partners. He holds a BS in Biomedical Engineering from the University of Virginia (Charlottesville, VA) and an MS in Biomedical Engineering from Johns Hopkins University School of Medicine (Baltimore, MD).

Joey Bose, MS

President

Dr. Hanna has served as Chief Scientific Officer of Cytonics since February 2008. Dr. Hanna has over 28 years’ experience in pharmaceutical research and development, specializing in the development of recombinant protein therapies. He has extensive knowledge of protein folding, purification, formulation, large-scale production, quality, and the regulatory requirements to obtain FDA new drug approval. Until 2004, Dr. Hanna was the Director of Process Development at Alexion Pharmaceutical, and prior to that he was a Group Leader at Bristol-Myers Squibb Pharmaceutical Research Institute. He also served a Principal Research Scientist at R.W. Johnson Pharmaceutical Research Institute (Raritan, NJ) for 7 years. Dr. Hanna received his BS degree from Cairo University (Giza, Egypt), received his PhD from City University of New York (New York City, NY), and completed a postdoctoral fellowship at Cornell University (Ithaca, NY).

Lewis Hanna, PhD

Chief Scientific Officer

Cytonics recently welcomed Tracy Goeken, MD to the company's Board of Directors. As a member of the Board, Dr. Goeken will help drive the company's direction and manage clinical trials. Dr. Goeken brings over 15 years' of expertise in the biopharmaceutical industry and currently serves as the Chief Medical Officer for Linical Americas, a contract research organization that provides the full spectrum of drug development services.

Prior to Linical, Dr. Goeken held positions at The Methodist Hospital Research Institute in Houston, Texas, Pharm-Olam International, Nuron Biotech, and Somahlution. During his tenure as Vice President of Clinical and Medical affairs at Nuron Biotech Inc., the company secured $80mm in financing for the commercialization and expansion of its vaccine Meningitec.

Tracy Goeken, MD

Board Member

Phil LoGrasso, Ph.D. joined the company’s growing Board of Directors in December of 2020. Dr. LoGrasso’s expertise in the biotechnology industry includes experience as a Program Director at the National Institute of Health (NIH), Research Fellow in drug discovery and development at Merck and Avera Pharmaceuticals, and as a senior analyst at GQG Partners (a $56B global hedge fund). Phil has spent almost three decades actively involved in forming relationships with Big Pharma, venture-backed biotech companies, academic researchers at the NIH, and biotech-focused hedge funds.

Mr. Ramseier is the President, co-founder and an equity member of BCI LifeSciences LLC. He has over forty years of origination and operations experience, building and commercializing new technologies. He was a Founder of The Sage Group, and has held senior level executive and board of directors positions with a number of companies in the life sciences industry, including: OncoTherapeutics, ImmuneTech Pharmaceuticals, Inc. (later Dura Pharmaceuticals), the Healthcare Industries Practice of Booz, Allen & Hamilton, G.D. Searle, and Pfizer Laboratories. Mr. Ramseier received his M.B.A. (with distinction) from the Amos Tuck School of Business Administration, Dartmouth College and his B.S. in Chemistry from Washington & Lee University.

Gordon Ramseier

Board Member

Gaetano Scuderi, MD is the Founder of Cytonics Corporation. Dr. Scuderi is a fellowship-trained (UCSD, San Diego, CA) spine surgeon who has practiced medicine since 1993. He was also appointed to Clinical Assistant Professor in the Department of Orthopedic Surgery of Stanford University. He graduated medical school from State University of New York (Buffalo, NY) and completed his Residency at University of Miami School of Medicine (Miami, FL). Dr. Scuderi has published over 45 scientific articles and has lectured world-wide. Dr. Scuderi currently practices orthopedic surgery in Jupiter, FL.

In addition to his practice and his role with Cytonics, Dr. Scuderi is a 4th degree black-belt in Jiu Jitsu and the founder/principle instructor of Scuderi Self Defense (Jupiter, FL). Dr. Scuderi’s love for this martial art is only surpassed by his passion for helping the sick and elderly reclaim their mobility and quality of life.

Gaetano Scuderi, MD

Founder and Chairman of the Board

Mr. Bose has over 15 years’ experience in biotechnology research development and healthcare investment banking. He began his career as a systems biology researcher at the University of Virginia and Johns Hopkins University, advancing the field of proteomics and elucidating the molecular drivers of various cancers. Mr. Bose then worked for two boutique healthcare investment banks in the South Florida region, bringing his expertise to the healthcare deal diligencing team. As CEO & President of Cytonics, Mr. Bose coordinates capital raising efforts, manages the company’s preclinical and clinical trials for lead drug candidate “CYT-108”, oversees the Freedom to Operate patent prosecution strategy, and develops relationships with potential strategic partners. He holds a BS in Biomedical Engineering from the University of Virginia (Charlottesville, VA) and an MS in Biomedical Engineering from Johns Hopkins University School of Medicine (Baltimore, MD).

Joey Bose, MS

President

Dr. Hanna has served as Chief Scientific Officer of Cytonics since February 2008. Dr. Hanna has over 28 years’ experience in pharmaceutical research and development, specializing in the development of recombinant protein therapies. He has extensive knowledge of protein folding, purification, formulation, large-scale production, quality, and the regulatory requirements to obtain FDA new drug approval. Until 2004, Dr. Hanna was the Director of Process Development at Alexion Pharmaceutical, and prior to that he was a Group Leader at Bristol-Myers Squibb Pharmaceutical Research Institute. He also served a Principal Research Scientist at R.W. Johnson Pharmaceutical Research Institute (Raritan, NJ) for 7 years. Dr. Hanna received his BS degree from Cairo University (Giza, Egypt), received his PhD from City University of New York (New York City, NY), and completed a postdoctoral fellowship at Cornell University (Ithaca, NY).

Lewis Hanna, PhD

Chief Scientific Officer

Cytonics recently welcomed Tracy Goeken, MD to the company's Board of Directors. As a member of the Board, Dr. Goeken will help drive the company's direction and manage clinical trials. Dr. Goeken brings over 15 years' of expertise in the biopharmaceutical industry and currently serves as the Chief Medical Officer for Linical Americas, a contract research organization that provides the full spectrum of drug development services.

Prior to Linical, Dr. Goeken held positions at The Methodist Hospital Research Institute in Houston, Texas, Pharm-Olam International, Nuron Biotech, and Somahlution. During his tenure as Vice President of Clinical and Medical affairs at Nuron Biotech Inc., the company secured $80mm in financing for the commercialization and expansion of its vaccine Meningitec.

Tracy Goeken, MD

Board Member

Phil LoGrasso, Ph.D. joined the company’s growing Board of Directors in December of 2020. Dr. LoGrasso’s expertise in the biotechnology industry includes experience as a Program Director at the National Institute of Health (NIH), Research Fellow in drug discovery and development at Merck and Avera Pharmaceuticals, and as a senior analyst at GQG Partners (a $56B global hedge fund). Phil has spent almost three decades actively involved in forming relationships with Big Pharma, venture-backed biotech companies, academic researchers at the NIH, and biotech-focused hedge funds.

Phil LoGrasso, Ph.D

Board Member

Mr. Ramseier is the President, co-founder and an equity member of BCI LifeSciences LLC. He has over forty years of origination and operations experience, building and commercializing new technologies. He was a Founder of The Sage Group, and has held senior level executive and board of directors positions with a number of companies in the life sciences industry, including: OncoTherapeutics, ImmuneTech Pharmaceuticals, Inc. (later Dura Pharmaceuticals), the Healthcare Industries Practice of Booz, Allen & Hamilton, G.D. Searle, and Pfizer Laboratories. Mr. Ramseier received his M.B.A. (with distinction) from the Amos Tuck School of Business Administration, Dartmouth College and his B.S. in Chemistry from Washington & Lee University.

Gordon Ramseier

Board Member

Investor Perks

Limited Time Investor Perks

Cytonics is disrupting the field of regenerative medicine with their innovative biologic therapies for osteoarthritis. Returning Reg A+ investors that make another investment will receive perks equivalent to one tier above their investment amount. Learn more about the investor perks below.

Premier

Tier 1

Invest $15,000 to $29,999

  • Complimentary consultation with a qualified physician (regional availability may differ)
  • Participation in scheduled quarterly calls with Cytonics’ senior management
Tier 2

Invest $30,000 to $74,999

  • All of the above
  • Complimentary APIC kit (sent to a qualified physician, regional availability may differ)

Insider

Tier 3

Invest $75,000 to $149,999

  • All of the above
  • Paid airfare to visit our research facilities and a dinner with Cytonics’ senior management
  • Complimentary consult with Gaetano Scuderi, MD and APIC treatment
Tier 4

Invest $150,000 to $249,999

  • All of the above
  • Complimentary flight (for two) to Jupiter, FL for a weekend stay at the Jupiter Beach Resort
  • Plus invitation to annual updates (dinners, calls) with Cytonics’ senior management

Elite

Tier 5

Invest Invest $250,000 or more

  • All of the above
  • Plus an active role in CYT-108 development, plus complimentary admission to industry conferences that Cytonics attends (such as the American Academy of Orthopedic Surgeons Annual Meeting)
Cytonics Is Pioneering Breakthrough Treatments For Osteoarthritis

Invest in our next growth phase as we prepare for Phase 1 human clinical trials.

Thank you! Please check your inbox for the Cytonics Investor Deck!
Oops! Something went wrong while submitting the form.

Biotech Investing 101

Leaving already?

Join the Cytonics mailing list to receive live investor updates!

Thank you! Please check your inbox for the Cytonics Investor Deck!
Oops! Something went wrong while submitting the form.